The present guideline updates prior JNC reports. 8. Causes of Secondary Hypertension with Clinical Indications and Diagnostic Screening Tests (2 of 3) . Am Fam Physician. Oct 1;90(7) JNC8 guidelines for the management of hypertension in adults. Armstrong C; Joint National Committee. However, the updated JnC-8 guidelines do not include beta- blockers as initial .. teshimaryokan.info+html. 5.
|Language:||English, Spanish, Indonesian|
|Genre:||Science & Research|
|ePub File Size:||28.46 MB|
|PDF File Size:||9.31 MB|
|Distribution:||Free* [*Regsitration Required]|
Hypertension guidelines from the Eighth Joint National Committee (JNC 8) are finally here. While we were waiting for JNC 8, the American Society. The Eighth Joint National Committee (JNC 8) recently released evidence-based recommendations on treatment thresholds, goals, and JNC 8 Guidelines for the Management of Hypertension in Adults. PDF; Print page. based guidelines,7,8 the Eighth Joint National Committee (JNC. 8) was initially appointed to create an updated treatment guideline for hypertension under the.
Journals About. Treatment does not need to be adjusted if it results in a systolic pressure lower than mm Hg, as long as it is not associated with adverse effects on health or quality of life. Referral to a physician with expertise in treating hypertension may be necessary for patients who do not reach the target blood pressure using these strategies. Compendia Alternative Payment Models. Currently Reading. Multiple Sclerosis. Blood pressure should be monitored and the treatment regimen adjusted until the target blood pressure is reached.
In the general population younger than 60 years, pharmacologic treatment should be initiated when the systolic pressure is mm Hg or higher, or when the diastolic pressure is 90 mm Hg or higher. The target systolic pressure in this population is less than mm Hg, and the target diastolic pressure is less than 90 mm Hg.
For persons 18 years or older with chronic kidney disease CKD or diabetes mellitus, the treatment threshold and target blood pressures are the same as those for the general population younger than 60 years i. There is no evidence that treating patients with CKD to a lower blood pressure goal slows the progression of the disease.
Similarly, there is no evidence from randomized controlled trials showing that treatment to a systolic pressure of less than mm Hg improves health outcomes in adults with diabetes and hypertension. In the general nonblack population, including those with diabetes, initial anti-hypertensive treatment should include a thiazide diuretic, calcium channel blocker, angiotensin-converting enzyme ACE inhibitor, or angiotensin receptor blocker ARB.
In the general black population, including those with diabetes, initial treatment should include a thiazide diuretic or calcium channel blocker. If the target blood pressure is not reached within one month after initiating therapy, the dosage of the initial medication should be increased or a second medication should be added thiazide diuretic, calcium channel blocker, ACE inhibitor, or ARB; do not combine an ACE inhibitor with an ARB.
Blood pressure should be monitored and the treatment regimen adjusted until the target blood pressure is reached. A third drug should be added if necessary; however, if the target blood pressure cannot be achieved using only the drug classes listed above, antihypertensive drugs from other classes can be used e.
Referral to a physician with expertise in treating hypertension may be necessary for patients who do not reach the target blood pressure using these strategies.
Adults with CKD and hypertension should receive an ACE inhibitor or ARB as initial or add-on therapy, based on moderate evidence that these medications improve kidney-related outcomes in these patients. Guideline developed by participants without relevant financial ties to industry?
Published source: Journal of the American Medical Association , December 18, Available at: Already a member or subscriber? Log in. This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference.
This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.
Contact afpserv aafp. Want to use this article elsewhere? Get Permissions.
Read the Issue. Sign Up Now. Oct 1, Issue. Am Fam Physician. From the AFP Editors.
Glucose Monitoring. Multiple Sclerosis. Pain Management. Parkinson Disease.
Precision Oncology. Women's Health. Media Insights.
Post-Conference Perspectives. Currently Viewing: Evidence-Based Diabetes Management January Currently Reading.
Nonincretin Drugs in Later-Stage Development. Attacking Complications to Kidney Problems in Diabetes: Atrial Fibrillation and Resistant Hypertension. Nutritional Supplements and Cardiovascular Health. Dangerous Liaisons: Obesity and Diabetes. Stakeholders Weigh In.
New Possibilities in Primary Care and Reimbursement.
January 21, Compared with previous hypertension treatment guidelines, the Joint National Committee JNC 8 guidelines advise higher blood pressure goals and less use of several types of antihypertensive medications. Patients will be asking about the new JNC 8 hypertension guidelines, which were published in the Journal of the American Medical Association on December 18, The new guidelines also introduce new recommendations designed to promote safer use of angiotensin converting enzyme ACE inhibitors and angiotensin receptor blockers ARBs.
Important changes from the JNC 7 guidelines 2 include the following: Several medications are now designated as later-line alternatives, including the following: The guidelines were informed by results of 5 key trials: Results showed a reduction in cerebrovascular events, heart failure, and overall mortality in patients treated to the DBP target level.